SINGAPORE (Apr 27): iX Biopharma has entered into a 10-year licensing agreement with Yiling Pharmaceutical in China for the licensing, supply, and distribution of Wafesil, a fast-dissolving sublingual sildenafil wafer for the treatment of male erectile dysfunction.

<strong>See also: <a href="https://www.theedgesingapore.com/ixbiopharmas-wafesil-granted-regulatory-approval-treatment-male-erectile-dysfunction-australia" target="_blank">iXBiopharma's Wafesil granted regulatory approval for treatment of male erectile dysfunction in Australia</a></strong>

Wafesil was formerly known as <a href="https://www.theedgesingapore.com/article/ix-biopharma%E2%80%99s-male-erectile-dysfunction-drug-stands-test" target="_blank">PheoniX</a>.

Under the agreement, iX Biopharma will manufacture and supply Wafesil to Yiling at an agreed supply price. The agreement will also provide Yiling with marketing authorisation and an exclusive license to market and distribute the drug in China.

Yiling will pay iX Biopharma an upfront and certain milestone payments prior to the commercialisation of the drug, whereby the milestone payments will be made upon the completion of bioequivalence studies, and on the first commercial supply of wafers to Yiling. Yiling has agreed to fund such studies, and regulatory submissions necessary for the registration of the product in China.

Yiling estimates the first five years of sales in China for Wafesil to be around RMB 700 – 800 million (or $140.7 - $160.7 million).

<strong>See also: <a href="https://www.theedgesingapore.com/news/company-news/ix-biopharma-secures-license-manufacture-cannabis-australia" target="_blank">iX Biopharma secures licence to manufacture cannabis in Australia</a></strong>

As of 9.27am, IX Biopharma shares traded at 0.04 cents higher, or 18.7% up, at 0.24 cents.

iX Biopharma enters China market with licensing agreement for erectile dysfunction drug

DBS suspends coverage of Bukit Sembawang Estates; keeps 'buy'

CGS-CIMB downgrades GKE with lower target price of 10 cents

Investors should focus on equities in the current environment with more defensive bias: Julius Baer

Businesses in Singapore eager to hire international talent with the rise of remote work

Putting consumer safety at the forefront of every retailer's agenda

ShopBack leverages Forter to grow securely

Lawrence Wong outlines vision for equality, safety Nets

iX Biopharma enters China market with licensing agreement for erectile dysfunction drug

Related Stories

Highlights

China's shock Covid shift adds fuel to world-beating stock rally

Related Stories

iX Biopharma reverses from losses to net profit of $3.7 mil in 1HFY2022 from out-licensing of Wafermine

iX Biopharma aims for stronger growth momentum with Seelos licensing deal

iX Biopharma 'warming up' with new outlicensing agreement with Seelos Therapeutics: PhillipCapital